Next-Generation Antibody Therapies Market Forecast 2015-2025; Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies

LONDON, June 22, 2015 /PRNewswire/ --

Next-generation antibody therapies- new study showing you trends, R&D progress, and predicted revenues
Where's the next-generation antibody therapies market heading? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 236-page report provides 126 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharmaceutical market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr Edwin Moses, CEO, Ablynx
- Tim Van Hauwermeiren , CEO, ArGEN-X
- The executive management team at Mersana Therapeutics

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see revenue forecasts to 2025 for the following submarkets:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Biosimilar antibodies

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

To see a report overview please email Sara Peerun on [email protected]

See revenue forecasts for products
How will leading next-generation antibody therapies perform to 2025 at world level? Our study forecasts sales of 7 products, including these brands:
• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor

Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 5 regional markets to 2025:
• US
• EU5
• Asia-Pacific
• Latin America
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that the Asia-Pacific, in particular, will continue to achieve high revenue growth to 2025. Developments worldwide in biosimilar regulation and next-generation antibody development will influence the market.

Leading companies and potential for market growth
Overall world revenue for next-generation antibody therapies will reach $2.3bn in 2015, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, investment from Big Pharma and increasing demand for chronic disease treatment will increase sales to 2025.

Our work shows you what organisations hold greatest potential. Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Other progress in next-generation antibody therapy development.

To see a report overview please email Sara Peerun on [email protected]

Our study also discusses these agents and technologies, among others:
• Site-specific linkers

• Glycosylation or glycoengineering
• Defucosylation
• Amino acid modification
• Enhanced antibody-dependent cell-mediated cytotoxicity (ADCC)
• Bispecific, trispecific and multi-specific antibodies
• Domain fragments
• Single-chain variable fragments
• Alternative scaffolds: DARPins, anticalins, Affibodies, Fynomers, Affilins, Adnectins and i-bodies
• Combination therapies
• Other novel antibody platforms

Next-generation antibody therapy R&D is strong in antibody-drug conjugates. Novel products and biobetters with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the next-generation antibody therapies industry?
Our new report discusses issues and events affecting the next-generation antibody therapies market. You will find discussions, including qualitative analyses:
• Approved products indicate a path to market acceptance
• Challenges exist with current monoclonal antibody therapies
• Big Pharma is investing heavily in next-generation pipelines
• Biosimilars may slow growth in the next-generation antibody market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Next-Generation Antibody Therapies Market Forecast 2015-2025: Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies report helps you
In summary, our 236-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the world next-generation antibody therapies market and 5 product categories - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for the leading 5 regional markets - US, EU5, Asia-Pacific, Latin America and Rest of the World
• Predicted revenues of 7 leading drugs to 2025 - see potentials of top products
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the next-generation antibody therapies market and leading companies. You find data, trends and predictions. Please order our report now.

Companies Listed
AbbVie
Abgenix (part of Amgen)
Ablynx
Actavis
AdAlta
ADC Therapeutics
Adnexus (acquired by Bristol-Myers Squibb)
Affibody
Affimed Therapeutics
Agensys
Albany Molecular Research Inc. (AMRI)
Alcon (subsidiary of Novartis)
Alexion
Allergan
Ambrx
Amgen
Applied Molecular Evolution (acquired by Eli Lilly)
Arana Therapeutics (part of Teva)
ArGEN-X
Astellas Pharma
AstraZeneca
Bayer
Bioceros
Biocon
Biogen Idec
BioNet Ventures
Biotest
BioWa (subsidiary of Kyowa Hakko Kirin)
Boehringer Ingelheim
Bristol-Myers Squibb
Catalent Pharma Solutions
Celgene
Celldex Therapeutics
Celltech (part of UCB)
Celltrion
Cephalon (part of Teva)
Chugai
Cilag (part of Johnson & Johnson)
Coldstream Laboratories (acquired by Piramal)
Concortis Biosystems (acquired by Sorrento Therapeutics)
Corixa (acquired by GSK)
Covagen
Crescendo Biologics
CSL Behring
CVie Therapeutics
Daewoong
Daiichi Sankyo
Defiante Farmaceutica
Delenex Therapeutics
Dendreon (defunct, assets acquired by Valeant)
Domantis (acquired by GSK)
Dr. Reddy's Laboratories
Dutalys (acquired by Roche)
Dyax Corporation
Eddingpharm
Eisai
Eli Lilly and Company (Lilly)
Emergent BioSolutions
ESBATech (part of Novartis)
ETH Zurich
FivePrime Therapeutics
Fresenius Biotech (part of Neopharm)
F-star
Fujifilm Diosynth Biotechnologies
GE Healthcare
Genentech (subsidiary of Roche)
Genmab
Gilead Sciences
Glenmark
Glycart (acquired by Roche)
Glycotope
Goodwin Biotechnology
GSK
Hospira (acquired by Pfizer)
IBC Pharmaceuticals (majority owned by Immunomedics)
Igenica
Immunocore
ImmunoGen
Immunomedics
Intas Biopharmaceuticals
Isu Abxis
Janssen Biotech (subsidiary of Johnson & Johnson)
Kalobios
Kyowa Hakko Kirin
Kyowa Medex (subsidiary of Kyowa Hakko Kirin)
LFB
Lindis Biotech
Lonza
MacroGenics
MedImmune (subsidiary of AstraZeneca)
Menarini
Mentrik Biotech
Merck & Co.
Merck Serono
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus
Micromet (acquired by Amgen)
Millennium Pharmaceuticals (subsidiary of Takeda)
Mitsubishi Tanabe
Molecular Partners
MorphoSys
MultiCell Immunotherapeutics
Neopharm
Novartis
Novartis Institutes for BioMedical Research
Novellus Biopharma
NovImmune
Ono Pharmaceutical
Oxford BioMedica
Oxford BioTherapeutics
Oxis Biotech
PDL BioPharma (part of AbbVie)
Pfizer
Pharmacyclics
Pharming Group
Pieris
Piramal Enterprises
PolyTherics
Probiomed
Progenics Pharmaceuticals
ProStrakan (acquired by Kyowa Hakko Kirin)
Redwood Science (acquired by Catalent)
Roche
Salix
Sanofi
Scil Proteins (owned by BioNet Ventures)
Seattle Genetics
Servier
Shire
Sigma-Aldrich Fine Chemicals (SAFC)
Sorrento Therapeutics
Spectrum Pharmaceuticals
Spirogen
Stelis Biopharma (subsidiary of Strides Arcolab)
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Synthon
Takeda
Talon Therapeutics
Teva
TG Therapeutics
TRION Pharma
Trion Research
UCB
Wyeth (acquired by Pfizer)
Xencor
Zydus Cadila

Other Organisations Mentioned in This Report
American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
European Medicines Agency (EMA)
Helmholtz Zentrum München
Karolinska Institute
Krankenhaus Nordwest
National Institute for Health and Care Excellence (NICE) (UK)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pharmaceutical and Medical Devices Agency (PMDA) (Japan)
Royal Institute of Technology
Swiss Federal Institute of Technology
Technische Universität München
US Food and Drug Administration (FDA)
US Patent Office
World Health Organization (WHO)

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on http://www.visiongain.com

SOURCE Visiongain